Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive ...

Sarepta Therapeutics (NASDAQ:SRPT) presented preliminary clinical data from ongoing phase I/II studies of two investigational ...

The FDA has granted Fast Track designation to BW-20805, an investigational small interfering RNA therapy for hereditary angioedema.

Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its ...

Shares of Sarepta Therapeutics SRPT rose 35% on Wednesday after the company announced early clinical data on two experimental ...

Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral ...

Wave Life Sciences shares plunged >50% after Phase 1 INLIGHT data for WVE-007 showed <1% placebo-adjusted weight loss at six ...

SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the ...

Investing.com -- Sarepta Therapeutics (NASDAQ:SRPT) shares rose 14% following the company’s release of initial clinical data ...

The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...